 AIM: explore value serum M2-pyruvate kinase (M2-PK) colorectal cancer (CRC) mass screening. METHODS: conducted molecular epidemiology study Hangzhou, China, year 2006 year 2008. Serum samples collected 93 CRC, 41 advanced adenomas, 137 adenomas, 47 non-adenomatous polyps, 158 normal participants community setting. Serum M2-PK carcinoembryonic antigen (CEA) measured using Enzyme-linked immunosorbent assay. SPSS 16.0 software used perform data analysis. Area receiver operating characteristic curve (AUC), sensitivity, specificities estimated serum M2-PK diagnosis colorectal lesions compared CEA. RESULTS: Average serum M2-PK value among 158 normal people 2.96 U/mL affected gender (P = 0.47) age (P = 0.59). Average serum M2-PK (U/mL) 14.75 among stage III 13.10 among stage II CRC patients, 4 times higher among normal people. Average serum M2-PK 8.58, 6.70, 5.13 2.51 U/mL among advanced adenoma, adenomas, non-adenomatous polyps, inflammatory bowel disease patients, respectively. AUC serum M2-PK greater CEA among colorectal lesions. AUC serum M2-PK 0.89 (0.84, 0.94) (95% confidence interval), higher CEA [0.70 (0.62-0.79)] CRC stage II, 0.89 (0.84-0.94) vs 0.73 (0.63-0.83) CRC stage III, 0.81 (0.74-0.86) vs 0.63 (0.53 - 0.73) advanced adenomas, 0.69 (0.64-0.76) vs 0.54 (0.47-0.60) adenomas, 0.69 (0.62-0.78) vs 0.58 (0.48-0.68) non-adenomatous polyps. diagnostic sensitivity colorectal lesions increased decrease cut-off value serum M2-PK. diagnostic sensitivity (%) serum M2-PK 100.00 CRC, 95.12 advanced adenoma, 82.48 adenoma, 82.98 non-adenomatous polyp. CRC cases missed 40.51% unnecessary colonoscopies avoided cut-off value 2.00 U/mL. CONCLUSION: Serum M2-PK used primary screening test CRC mass screening. may promising non-invasive biomarker CRC early detection.